CSPC Pharmaceutical Group Limited (01093) at a glance
Code
01093
Company
CSPC Pharmaceutical Group Limited
Local name
CSPC PHARMA
Market
Hong Kong Stock Exchange
Share price
HK$8.53 -0.10 (-1.10%)Nov 11 close
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
CSPC Pharmaceutical Group Limited (01093) Stock Price History
CSPC Pharmaceutical Group Limited closed at HK$8.53 on Nov 11, 2026, −6.1% over 1 month, +12.8% over 1 year.
Price5-day MA25-day MAHang Seng IndexDisclosures
1-Month HighHK$9.07Oct 13
1-Month LowHK$7.85Nov 3
1-Week Change+2.0%vs Nov 4
1-Month Change−6.1%vs Oct 9
If you had invested HK$10,000 1 month ago, it would be worth HK$9,452 today (−5.5%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved +0.2%, while this stock moved −5.5%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 11 (Wed)
HK$8.53
−0.10
−1.10%
Nov 10 (Tue)
HK$8.63
+0.20
+2.31%
Nov 9 (Mon)
HK$8.43
−0.02
−0.24%
Nov 6 (Fri)
HK$8.45
−0.13
−1.52%
Nov 5 (Thu)
HK$8.58
+0.22
+2.63%
Nov 4 (Wed)
HK$8.36
+0.51
+6.50%
Nov 3 (Tue)
HK$7.85
−0.04
−0.57%
Nov 2 (Mon)
HK$7.90
+0.03
+0.38%
Oct 30 (Fri)
HK$7.87
−0.17
−2.18%
Oct 29 (Thu)
HK$8.04
+0.07
+0.88%
Price5-day MA25-day MAHang Seng IndexDisclosures
3-Month HighHK$10.07Sep 30
3-Month LowHK$7.85Nov 3
1-Month Change−6.1%vs Oct 9
3-Month Change−2.0%vs Aug 11
If you had invested HK$10,000 3 months ago, it would be worth HK$9,805 today (−2.0%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −5.2%, while this stock moved −2.0%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 11 (Wed)
HK$8.53
−0.10
−1.10%
Nov 10 (Tue)
HK$8.63
+0.20
+2.31%
Nov 9 (Mon)
HK$8.43
−0.02
−0.24%
Nov 6 (Fri)
HK$8.45
−0.13
−1.52%
Nov 5 (Thu)
HK$8.58
+0.22
+2.63%
Nov 4 (Wed)
HK$8.36
+0.51
+6.50%
Nov 3 (Tue)
HK$7.85
−0.04
−0.57%
Nov 2 (Mon)
HK$7.90
+0.03
+0.38%
Oct 30 (Fri)
HK$7.87
−0.17
−2.18%
Oct 29 (Thu)
HK$8.04
+0.07
+0.88%
Price25-day MA75-day MAHang Seng IndexDisclosures
6-Month HighHK$10.07Sep 30
6-Month LowHK$6.65Jun 25
3-Month Change−2.0%vs Aug 11
6-Month Change+4.0%vs May 11
If you had invested HK$10,000 6 months ago, it would be worth HK$10,402 today (+4.0%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −7.9%, while this stock moved +4.0%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$8.53
+8.5%
Oct 2026
HK$7.87
−21.9%
Sep 2026
HK$10.07
+9.0%
Aug 2026
HK$9.24
+7.7%
Jul 2026
HK$8.58
+23.1%
Jun 2026
HK$6.97
−7.1%
May 2026
HK$7.50
−10.8%
Price25-day MA75-day MAHang Seng IndexDisclosures
52-Week HighHK$10.69Jan 29
52-Week LowHK$6.65Jun 25
Year to Date+1.1%vs Dec 31
From 52-Week High−20.2%Jan 29
If you had invested HK$10,000 1 year ago, it would be worth HK$11,283 today (+12.8%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −8.9%, while this stock moved +12.8%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$8.53
+8.5%
Oct 2026
HK$7.87
−21.9%
Sep 2026
HK$10.07
+9.0%
Aug 2026
HK$9.24
+7.7%
Jul 2026
HK$8.58
+23.1%
Jun 2026
HK$6.97
−7.1%
May 2026
HK$7.50
−10.8%
Apr 2026
HK$8.41
−7.6%
Mar 2026
HK$9.10
−8.1%
Feb 2026
HK$9.90
+3.1%
Jan 2026
HK$9.60
+13.7%
Dec 2025
HK$8.44
+6.7%
Nov 2025
HK$7.91
+3.4%
Price13-week MA26-week MAHang Seng Index
3-Year HighHK$11.19Sep 1, 2025
3-Year LowHK$4.37Jan 6, 2025
Annualized Return+7.6%
Max Drawdown−40.2%
If you had invested HK$10,000 3 years ago, it would be worth HK$12,453 today (+24.5%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved +39.3%, while this stock moved +24.5%.
Yearly Closes
Year
Year-End Close
Yearly %
2026 (YTD)
HK$8.53
+1.1%
2025
HK$8.44
―
Price13-week MA26-week MAHang Seng Index
5-Year HighHK$11.19Sep 1, 2025
5-Year LowHK$4.37Jan 6, 2025
Annualized Return+0.5%
Max Drawdown−56.6%
If you had invested HK$10,000 5 years ago, it would be worth HK$10,277 today (+2.8%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −2.9%, while this stock moved +2.8%.
Yearly Closes
Year
Year-End Close
Yearly %
2026 (YTD)
HK$8.53
+1.1%
2025
HK$8.44
―
Price1-year MA2-year MAHang Seng Index
All-Time HighHK$12.79May 2018
All-Time LowHK$0.45Jul 2006
Total Change+524.0%vs Jun 2003
Annualized Return+8.1%
If you had invested HK$10,000 in Jun 2003, it would be worth HK$62,399 today (+524.0%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved +122.9%, while this stock moved +524.0%.
Yearly Closes
Year
Year-End Close
Yearly %
2026 (YTD)
HK$8.53
+1.1%
2025
HK$8.44
+77.3%
2024
HK$4.76
−34.4%
2023
HK$7.26
−11.5%
2022
HK$8.20
−3.2%
2021
HK$8.47
+6.5%
2020
HK$7.95
−17.8%
2019
HK$9.68
+64.4%
2018
HK$5.89
−28.4%
2017
HK$8.22
+90.6%
2016
HK$4.31
+4.6%
2015
HK$4.13
+15.8%
2014
HK$3.56
+11.8%
2013
HK$3.19
+174.6%
2012
HK$1.16
+30.3%
2011
HK$0.89
−60.6%
2010
HK$2.26
+0.7%
2009
HK$2.25
+58.4%
2008
HK$1.42
−6.2%
2007
HK$1.51
+163.5%
2006
HK$0.57
−8.3%
2005
HK$0.63
−41.5%
2004
HK$1.07
−17.1%
2003
HK$1.29
―
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jun 2003). Please check the latest prices before trading.
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No.36Disclosure2026/11/06 20:05
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECTION FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECTION FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION AND RESISTANT HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TABLETS IN COMBINATION WITH DAPAGLIFLOZIN TABLETS AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS ACHIEVES POSITIVE TOPLINE RESULTS
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF SYS6043 (B7-H3 ADC) FOR THE TREATMENT OF ADVANCED BREAST CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF ANTI-PD-1/IL-15 BIFUNCTIONAL FUSION PROTEIN SYS6090 (JMT108) MONOTHERAPY IN ADVANCED SOLID TUMOURS PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER PRESENTED AS A PROFFERED PAPER PRESENTATION AT THE ESMO CONGRESS 2026 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
事業の状況
VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB FOR THE TREATMENT OF HER2-POSITIVE ADVANCED GASTRIC CANCER/GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER OFFICIALLY INITIATED IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION OFFICIALLY INITIATED IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002 AS MONOTHERAPY FOR THE TREATMENT OF ADVANCED CERVICAL CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE 2026 ANNUAL GLOBAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS 2026)
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF EFMEDAGLUTIDE ALFA INJECTION IN COMBINATION WITH METFORMIN IN CHINESE ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS PRESENTED IN A SHORT ORAL DISCUSSION AT THE 62ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD 2026)
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE IB CLINICAL TRIAL OF JMT206 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST STUDY CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC HARBOURING EGFR EXON 20 INSERTION MUTATIONS ACHIEVES POSITIVE TOPLINE RESULTS
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE TREATMENT OF ADVANCED BREAST CANCER OFFICIALLY INITIATED IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ADULT PATIENTS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
事業の状況
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA IN CHINA FOR THE TREATMENT OF PATIENTS WITH ACTIONABLE GENOMIC ALTERATION-NEGATIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL DATA OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF SYSTEMIC TREATMENT-NAIVE, ACTIONABLE GENOMIC ALTERATION-NEGATIVE ADVANCED NSCLC ORALLY PRESENTED AT THE 2026 WORLD CONFERENCE ON LUNG CANCER (WCLC)